Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at ...

A retrospective study of an artificial intelligence program for reading 3D mammography scans illustrated the pros, cons and ...

Days after the Women’s Health Initiative, one of the largest and longest women’s health studies in the world, announced that ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will ...

Over the next four months, the Vaccine Integrity Project will hold information-gathering sessions with medical associations, ...

The pipeline purge comes less than a year after Caribou cut 12% of staff and ended its natural killer cell therapy program in ...

Big Pharma's M&A plans will likely take a hit if the U.S. government under the Trump administration lives up to its threats ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...